Optical biosensing of markers of mucosal inflammation

Obdulia Covarrubias-Zambrano,Massoud Motamedi,Bill T Ameredes,Bing Tian,William J Calhoun,Yingxin Zhao,Allan R Brasier,Madumali Kalubowilage,Aruni P Malalasekera,Asanka S Yapa,Hongwang Wang,Christopher T Culbertson,Deryl L Troyer,Stefan H Bossmann
DOI: https://doi.org/10.1016/j.nano.2021.102476
Nanomedicine
Abstract:We report the design and adaptation of iron/iron oxide nanoparticle-based optical nanobiosensors for enzymes or cytokine/chemokines that are established biomarkers of lung diseases. These biomarkers comprise ADAM33, granzyme B, MMP-8, neutrophil elastase, arginase, chemokine (C-C motif) ligand 20 and interleukin-6. The synthesis of nanobiosensors for these seven biomarkers, their calibration with commercially available enzymes and cytokines/chemokines, as well as their validation using bronchoalveolar lavage (BAL) obtained from a mouse model of TLR3-mediated inflammation are discussed here. Exhaled Breath Condensate (EBC) is a minimally invasive approach for sampling airway fluid in the diagnosis and management of various lung diseases in humans (e.g., asthma, COPD and viral infections). We report the proof-of-concept of using human EBC in conjunction with nanobiosensors for diagnosis/monitoring airway inflammation. These findings suggest that, with nanosensor technology, human EBC can be utilized as a liquid biopsy to monitor inflammation/remodeling in lung disease.
What problem does this paper attempt to address?